Achilles Therapeutics PLC ACHL
$1.48 $0.01 (0.68%) 1D
Last Updated: Mar 20, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Achilles Therapeutics PLC Stock Halal?
Shariah Compliance Analysis of ACHL Stock
Germany Health Care Micro Cap No. As of September 2026, Achilles Therapeutics PLC (ACHL) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Achilles Therapeutics PLC does not pass Musaffa's business and financial screening criteria.
Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. The company is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. The company refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.
ACHL Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Achilles Therapeutics PLC is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Achilles Therapeutics PLC (ACHL) Chart
Financial Metrics & Statements of Achilles Therapeutics PLC (ACHL)
FAQ's for Achilles Therapeutics PLC (ACHL)
- As of September 2026, Achilles Therapeutics PLC ACHL is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Achilles Therapeutics PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Achilles Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Achilles Therapeutics PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Achilles Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Achilles Therapeutics PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Achilles Therapeutics PLC (ACHL)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
